Keppra and Deafness neurosensory - a phase IV clinical study of FDA data
Summary:
Deafness neurosensory is reported as a side effect among people who take Keppra (levetiracetam), especially for people who are female, 40-49 old, also take Ativan, and have Blood cholesterol decreased.
The phase IV clinical study analyzes which people have Deafness neurosensory when taking Keppra. It is created by eHealthMe based on reports of 70,297 people who have side effects when taking Keppra from the FDA, and is updated regularly.
What is Keppra?
Keppra has active ingredients of levetiracetam. It is often used in epilepsy. eHealthMe is studying from 73,504 Keppra users. Check the latest studies of Keppra.
What is Deafness neurosensory?
Deafness neurosensory is found to be associated with 522 drugs and 947 conditions by eHealthMe. Check the latest studies of Deafness neurosensory.
70,297 people reported to have side effects when taking Keppra.
Among them, 14 people (0.02%) have Deafness neurosensory.
Among these 14 people:
What is the gender of people who have Deafness neurosensory when taking Keppra? *
- female: 85.71 %
- male: 14.29 %
What is the age of people who have Deafness neurosensory when taking Keppra? *
- 0-1: 9.09 %
- 2-9: 27.27 %
- 10-19: 9.09 %
- 20-29: 0.0 %
- 30-39: 18.18 %
- 40-49: 27.27 %
- 50-59: 9.09 %
- 60+: 0.0 %
What are other drugs people take besides Keppra? *
- Zonegran: 3 people, 21.43%
- Temodar: 3 people, 21.43%
- Lamictal: 3 people, 21.43%
- Perampanel: 3 people, 21.43%
- Famvir: 3 people, 21.43%
- Dilantin: 3 people, 21.43%
- Tegretol: 3 people, 21.43%
- Ceftriaxone: 3 people, 21.43%
- Trileptal: 3 people, 21.43%
- Ativan: 3 people, 21.43%
What are other side effects people have besides Deafness neurosensory? *
- Chest Pain: 4 people, 28.57%
- Enlarged Heart: 4 people, 28.57%
- Sinusitis (inflammation of sinus): 4 people, 28.57%
- Ecchymosis (a discoloration of the skin resulting from bleeding underneath): 4 people, 28.57%
- Hypoacusis (loss of hearing): 4 people, 28.57%
- Gastrointestinal Injury (injury to gastrointestinal tract): 3 people, 21.43%
- Fever: 3 people, 21.43%
- Febrile Neutropenia (fever with reduced white blood cells): 3 people, 21.43%
- Mouth Ulcers: 3 people, 21.43%
- Multiple-Drug Resistance: 3 people, 21.43%
What are the existing conditions these people have? *
- Herpes Simplex (herpes simplex is a common viral infection): 3 people, 21.43%
- Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 3 people, 21.43%
- Blood Cholesterol Decreased: 3 people, 21.43%
- Metastases To Breast (cancer spreads to brain): 1 person, 7.14%
- Metastases To Bone (cancer spreads to bone): 1 person, 7.14%
- Infantile Spasms: 1 person, 7.14%
- Hepatitis C: 1 person, 7.14%
- Glioma (a type of tumour that starts in the brain or spine): 1 person, 7.14%
- Astrocytoma (tumour of the brain that originate in a particular kind of glial-cells): 1 person, 7.14%
- Asthma: 1 person, 7.14%
* Approximation only. Some reports may have incomplete information.
Do you take Keppra and have Deafness neurosensory?
- Check whether Deafness neurosensory is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Keppra:
- Keppra (73,504 reports)
Deafness neurosensory treatments and more:
- Deafness neurosensory (4,434 reports)
How severe was Deafness neurosensory and when was it recovered:
Expand to all the drugs that have ingredients of levetiracetam:
Sub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Keppra:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Deafness neurosensory:
- Deafness neurosensory (522 drugs)
Browse all the conditions that are associated with Deafness neurosensory:
- Deafness neurosensory (947 conditions)
Related publications that referenced our studies
- Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .
- Spengler DC, Montouris GD, Hohler AD, "Levetiracetam as a possible contributor to acute kidney injury", Clinical therapeutics, 2014 Aug .
- Almeida DM, Jean MR, Chystsiakova A, Monahan E, Oliveira SB, Monteiro IM, "Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report", Pancreas, 2013 Jan .
- Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .
- Spengler DC, Montouris GD, Hohler AD, "Levetiracetam as a possible contributor to acute kidney injury", Clinical therapeutics, 2014 Aug .
- Almeida DM, Jean MR, Chystsiakova A, Monahan E, Oliveira SB, Monteiro IM, "Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report", Pancreas, 2013 Jan .
How the study uses the data?
The study uses data from the FDA. It is based on levetiracetam (the active ingredients of Keppra) and Keppra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of K-Tab and Diflucan - 19 seconds ago
- Levetiracetam and Linezolid drug interactions for women aged 40-49 - 25 seconds ago
- Drug interactions of Imitrex and Metoprolol Succinate - 27 seconds ago
- Asthma and Incoherent - 28 seconds ago
- Drug interactions of Medroxyprogesterone Acetate and Lactulose - 31 seconds ago
- Could Cosentyx cause Salivary Hypersecretion? - 33 seconds ago
- Erosive Duodenitis and drugs of ingredients of nitroglycerin - 41 seconds ago
- Vyvanse vs. L-Tyrosine, side effect and effectiveness comparison - 45 seconds ago
- Could Tracleer cause Hip Fracture? - 51 seconds ago
- Drug interactions of Janumet Xr and Zofran - 54 seconds ago